Insulet Corporation (NASDAQ:PODD) is among the 10 High Growth S&P 500 Stocks to Buy Now. Truist on February 19, 2026, lowered ...

Insulet’s modeled fair value has been trimmed from US$369.64 to US$354.40, signaling a more measured view of upside in the current setup. That shift lines up with Street research that is resetting ...

Insulet Stock: why GLP-1 fears are overblown, with growth driven by Europe/MENA expansion. Read here for a detailed analysis on PODD stock.

Insulet jumps after Q4 EPS and revenue beat, margin expansion and record Omnipod growth power a strong 2025 finish and upbeat ...

Its Q4 revenue jumped ~29% YoY on a constant currency basis to $783.8M, exceeding the consensus by $15.1M, as its revenue ...

Insulet Corporation (NASDAQ:PODD) is one of the 10 best healthcare equipment stocks to buy according to hedge funds. On February 4, Stifel lowered its price target on Insulet Corporation (NASDAQ:PODD) ...

The prices paid for the shares ranged from $238.55 to $241.56. Following the transaction, McEvoy directly owns 13,916 shares of Insulet. According to InvestingPro analysis, the stock appears ...

Insulet Corporation PODD stock is trading higher on Wednesday after the company reported better-than-expected fourth-quarter ...

Insulet Corp. (PODD) on Wednesday reported fourth-quarter profit of $101.6 million.

Shares of Insulet Corp. PODD rallied 3.10% to $249.38 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 1.04% to 6,837.75 and ...

In its upcoming report, Insulet (PODD) is predicted by Wall Street analysts to post quarterly earnings of $1.48 per share, reflecting an increase of 28.7% compared to the same period last year.

According to TipRanks, Newitter is a 5-star analyst with an average return of 10.0% and a 49.59% success rate. Newitter covers the Healthcare sector, focusing on stocks such as Inspire Medical Systems ...